A randomized trial of bevacizumab for newly diagnosed glioblastoma - Test2 - elhamkhani - TriplyDB

A randomized trial of bevacizumab for newly diagnosed glioblastoma

A randomized trial of bevacizumab for newly diagnosed glioblastoma

http://www.wikidata.org/entity/Q30410163

about

Antiangiogenic therapy for high-grade glioma Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review High-grade glioma management and response assessment-recent advances and current challenges Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve Immune Evasion Strategies of Glioblastoma Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma A Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015 Stereotactic Radiosurgery for Glioblastoma VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside Advances in the treatment of newly diagnosed glioblastoma Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction Bevacizumab for glioblastoma Development of targeted therapies in treatment of glioblastoma Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis Current trends in the surgical management and treatment of adult glioblastoma Targeting Aggressive Cancer Stem Cells in Glioblastoma Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges Immunotherapy advances for glioblastoma Medical management of brain tumors and the sequelae of treatment.Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Polymeric drug delivery for the treatment of glioblastoma Ephs and Ephrins in malignant gliomas Contemporary murine models in preclinical astrocytoma drug development To what extent will 5-aminolevulinic acid change the face of malignant glioma surgery?Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Therapeutic Potential of Curcumin for the Treatment of Brain Tumors Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Prospects of immune checkpoint modulators in the treatment of glioblastoma Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs What next for newly diagnosed glioblastoma?

P2860

Q24193485-5E1614C9-1A3F-4036-8DAE-8D21F6812C57 Q26739012-BAB9567F-231E-4490-9768-266E3E9EF63B Q26740664-492F0552-199F-4FD7-8A7D-0D979AB32FA8 Q26742107-2D27F0B3-D9A3-4B8D-AE88-0F9B8FA90796 Q26764947-EA2E0B9C-9048-47EA-B07B-D7E9353D8506 Q26765855-B2F4DD55-773D-4D43-A144-6CA18FFECF6A Q26767169-A37C0096-9126-45B8-A7E2-D3B212014B25 Q26767359-DD874C5D-511A-4CB5-B964-D22A5D484972 Q26768680-B99AF8B1-BF84-4C82-9525-20193D28D596 Q26770678-41BC323A-464C-405B-9DD0-A2DEA659537F Q26773514-95099E1D-5732-4DF3-9B08-9931478EC801 Q26774717-39DF98F1-25D4-4CEF-85C8-1D1FA848E0D4 Q26776307-9F848EB8-B9A3-4047-B4FB-9993A8A70F11 Q26778787-E4995CA8-3CD8-4CC8-B791-D0C36835BAE3 Q26779221-20327A6D-B075-4075-8D28-B359AE096447 Q26783779-21681BC4-39C6-4087-A754-7FDDC50A6B4C Q26799854-BA1559F6-ED05-41E0-AEC1-22433468A195 Q26799983-75405FD4-7931-4514-8909-6240D441386D Q26801351-3CDBEF2F-3446-4492-826D-4ACCA848CB31 Q26822717-5DAEF316-7B30-4EB8-A32E-67017382AA2A Q26824777-D6B7AD23-BCB1-4F4D-B535-474D51C676E5 Q26825769-9FAE10D4-2282-4E2B-929F-669D33D42859 Q26830388-E8D1559B-D7BB-4E0A-98C0-0154B0CA55B8 Q26853308-824ADFB9-BE97-4CEB-AFE6-196F1254696D Q26862516-48FD5245-4505-457A-B832-EAE41301A9A1 Q26866513-CF276FB5-9F21-4FE4-A34A-833A9097B4DC Q26992174-04748801-FBCB-4DB3-8CCC-B50317D6B141 Q26998111-6B0F5B12-04C3-48CB-BF83-6A2314151608 Q27001560-28D52525-9B04-4160-8030-CD904467FD72 Q27010046-94483200-D2DE-4112-AC1A-B240019D37EE Q27015780-83273B6F-D291-4451-B2DA-7298969EE5A5 Q27026937-53AA4842-6384-4DF8-8469-B8215A5285E9 Q27028189-5EC3AC8C-4BF7-486B-9047-1C756605EE42 Q27310843-D9AEA3B3-AFAC-4BB4-B2E6-B26CDB21C2AD Q27853219-06A2F03E-1F53-4EDE-B9F2-9A32A9FBBAD3 Q28071572-87AE3155-9656-4323-8126-8BDC2DA48EE2 Q28078539-468674B7-396D-4BAB-8F21-CEF3331CA1BA Q28081371-4BF0C78D-36C8-48CA-B031-703F90B41BAF Q28082603-8A2ABBE8-10CA-4D87-B439-1B00CDA62CC6 Q28086839-86D08A47-8924-45A1-9923-3D1EE1A81BE6

P2860

A randomized trial of bevacizumab for newly diagnosed glioblastoma

http://www.wikidata.org/entity/Q30410163

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A randomized trial of bevacizumab for newly diagnosed glioblastoma

@ast

A randomized trial of bevacizumab for newly diagnosed glioblastoma

@en

type

label

A randomized trial of bevacizumab for newly diagnosed glioblastoma

@ast

A randomized trial of bevacizumab for newly diagnosed glioblastoma

@en

prefLabel

A randomized trial of bevacizumab for newly diagnosed glioblastoma

@ast

A randomized trial of bevacizumab for newly diagnosed glioblastoma

@en

P1433

Q30410163-7B400C28-00DF-4106-BEAD-F484E8D1A4EE

P1476

Q30410163-89D9B6B9-499E-4B09-A186-586DBAE3BFCF

P2093

Q30410163-0C11B6F5-ECEC-4E4B-86B8-0F1DA9F23049

Q30410163-0D1ED672-339C-42A8-ADA0-83706F986825

Q30410163-1F638A5D-A824-4C74-A5D3-9F7492072A59

Q30410163-39DCDABB-97B5-44B7-AB17-1EBF810CCF97

Q30410163-3F90AAF5-FC2E-4457-9D2D-647E5AA3E303

Q30410163-4B15820C-843B-4E74-AA8D-CF32B5599F54

Q30410163-501D4A22-EA4D-4C50-B5E2-E2C25F6F5491

Q30410163-59A6680C-53BD-4F42-AD5C-A6D66858BE38

Q30410163-627A92CE-0153-4DF9-805B-A76323672F77

Q30410163-7D61B1F5-9E8A-422D-8C81-B7008E4B591D

P2860

Q30410163-01497A74-E799-4A8B-9FEC-88328E32467A

Q30410163-1F84E6FB-9DB2-42F4-8BBA-F17042D06294

Q30410163-20DED622-CB79-48AA-ACD5-F588134B67F4

Q30410163-24DA4ED3-633C-48EC-8F1B-2EF0E564C55E

Q30410163-295C1E5A-68A0-492D-89E8-851644D19569

Q30410163-390B8F37-D409-4E64-82AA-E465F864FACE

Q30410163-435CEBBC-0D71-4280-ACF3-C0C2146124BB

Q30410163-4741B713-4A65-4BA3-8EB6-48704403884B

Q30410163-484FAA0B-2F4D-4E24-9EE5-E149662D0230

Q30410163-4D4CBC4F-9C50-4F30-9A94-EB37BC21A6E4

P304

Q30410163-014EEE64-FC3E-42C4-9297-A473FD2022A2

P31

Q30410163-7A061C0A-C30D-4910-9FD1-883A24A14CDE

P356

Q30410163-DADD0470-6A61-4786-9584-D5CA24CDF85B

P407

Q30410163-FDD7CF58-52E7-4A94-9293-AF1EE9163A0B

P433

Q30410163-4D9718FF-2AB6-4A66-A35C-534CE3C5980C

P478

Q30410163-5332B9CB-187E-4C2E-A66F-19F51B58054D

P50

Q30410163-2507DC07-535B-4F6B-B024-C901DA0E8346

Q30410163-300D5A68-9BE2-4763-BEBE-6B209F2CBAA3

Q30410163-9244C744-D61D-4DB2-8943-1CB2611FB3F1

P577

Q30410163-BE5D1190-EA49-4D15-8016-97563F39BF78

P698

Q30410163-25441059-7DB7-4B12-9BF4-42B0DCAE0926

P921

Q30410163-45769963-EB26-4286-9034-625F881FAFBE

P932

Q30410163-08D01FF3-71CF-4C50-B102-5BD842185893

P356

P1433

The New England Journal of Medicine

P1476

A randomized trial of bevacizumab for newly diagnosed glioblastoma

@en

P2093

Arnab Chakravarti

http://www.w3.org/2001/XMLSchema#string

David G Brachman

http://www.w3.org/2001/XMLSchema#string

David Schiff

http://www.w3.org/2001/XMLSchema#string

Deborah T Blumenthal

http://www.w3.org/2001/XMLSchema#string

Erik P Sulman

http://www.w3.org/2001/XMLSchema#string

Howard Colman

http://www.w3.org/2001/XMLSchema#string

Ivo W Tremont-Lukats

http://www.w3.org/2001/XMLSchema#string

James J Dignam

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Wefel

http://www.w3.org/2001/XMLSchema#string

Kenneth D Aldape

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Response criteria for glioma.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Evaluation of survival data and two new rank order statistics arising in its consideration.

P304

699-708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1308573

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

Volker W. Stieber

Maria Werner-Wasik

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24552317

http://www.w3.org/2001/XMLSchema#string

P921

P932

4201043

http://www.w3.org/2001/XMLSchema#string